Holly A. Bolton

Holly A. Bolton

Auto-generated profile, based on publicly available information

Holly A. Bolton

T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW, 2042, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2013 in Nature Immunology
Verified
Journal Article
Open access
PDF file
BRBen Roediger
Ben Roediger
RKRyan Kyle
Ryan Kyle
KYKwok Ho Yip
Kwok Ho Yip
NSNital Sumaria
Nital Sumaria
TGThomas V Guy
Thomas V Guy
WWWolfgang Weninger
Wolfgang Weninger
Innate lymphoid cells (ILCs) have been found in gut and lungs. Weninger and colleagues identify IL-13-producing ILCs in the skin, where they interact with mast cells and regulate allergic responses. Type 2 immunity is critical for defense against cutaneous infections but also underlies the development of allergic skin diseases. We report the identification in normal mouse dermis of an abundant, phenotypically unique group 2 innate lymphoid cell (ILC2) subset that depended on interleukin 7 (IL-7) and constitutively produced IL-13. Intravital multiphoton microscopy showed that dermal ILC2 cells specifically interacted with mast cells, whose function was suppressed by IL-13. Treatment of mice deficient in recombination-activating gene 1 (Rag1−/−) with IL-2 resulted in the population expansion of activated, IL-5-producing dermal ILC2 cells, which led to spontaneous dermatitis characterized by eosinophil infiltrates and activated mast cells. Our data show that ILC2 cells have both pro- and anti-inflammatory properties and identify a previously unknown interactive pathway between two innate populations of cells of the immune system linked to type 2 immunity and allergic diseases.

1 December 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
BRBen Roediger
Ben Roediger
RKRyan Kyle
Ryan Kyle
STSzun S. Tay
Szun S. Tay
AMAndrew Mitchell
Andrew Mitchell
HBHolly A. Bolton
Holly A. Bolton
WWWolfgang Weninger
Wolfgang Weninger

24 August 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HBHolly A. Bolton
Holly A. Bolton
EZErhua Zhu
Erhua Zhu
ATAlexandra M. Terry
Alexandra M. Terry
TGThomas V. Guy
Thomas V. Guy
WKWoon-Puay Koh
Woon-Puay Koh
BGBarbara Fazekas de St. Groth
Barbara Fazekas de St. Groth
Regulatory T cells (Tregs) have been shown to enhance immune reconstitution and prevent graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation; however, it is unclear how Tregs mediate these effects. Here, we developed a model to examine the mechanism of Treg-dependent regulation of immune reconstitution. Lymphopenic mice were selectively reconstituted with Tregs prior to transfer of conventional CD4+ T cells. Full Treg reconstitution prevented the rapid oligoclonal proliferation that gives rise to pathogenic CD4 effector T cells, while preserving the slow homeostatic form of lymphopenia-induced peripheral expansion that repopulates a diverse peripheral T cell pool. Treg-mediated CTLA-4–dependent downregulation of CD80/CD86 on DCs was critical for inhibition of rapid proliferation and was a function of the Treg/DC ratio achieved by reconstitution. In an allogeneic BM transplant model, selective Treg reconstitution before T cell transfer also normalized DC costimulation and provided complete protection against GVHD. In contrast, cotransfer of Tregs was not protective. Our results indicate that achieving optimal recovery from lymphopenia should aim to improve early Treg reconstitution in order to increase the relative number of Tregs to DCs and thereby inhibit spontaneous oligoclonal T cell proliferation.

1 March 2016 in Immunology & Cell Biology
Verified
Journal Article
Closed access
ESElena Shklovskaya
Elena Shklovskaya
ATAlexandra M Terry
Alexandra M Terry
TGThomas V Guy
Thomas V Guy
ABAdrian Buckley
Adrian Buckley
HBHolly A Bolton
Holly A Bolton
BGBarbara Fazekas de St Groth
Barbara Fazekas de St Groth

24 May 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
TGThomas V. Guy
Thomas V. Guy
ATAlexandra M. Terry
Alexandra M. Terry
HBHolly A. Bolton
Holly A. Bolton
DHDavid G. Hancock
David G. Hancock
ESElena Shklovskaya
Elena Shklovskaya
BGBarbara Fazekas de St Groth
Barbara Fazekas de St Groth

18 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
TGThomas V. Guy
Thomas V. Guy
ATAlexandra M. Terry
Alexandra M. Terry
HBHolly A. Bolton
Holly A. Bolton
DHDavid G. Hancock
David G. Hancock
EZErhua Zhu
Erhua Zhu
BGBarbara Fazekas de St Groth
Barbara Fazekas de St Groth
Collaboration between tumor-specific CD4 + T cells and B cells in anti-cancer immunity